Your idea isn't totally out of reality.
If you take a look at LI KA SHING's biotech company HUTCHMED's pipeline targets (below):
- Gastric Cancer
- NSCLC
- Breast Cancer
Might as well license something that targets HER-2 receptors, with the possibility of also expanding into TIGIT, LAG3 etc.
Take a 10% equity stake in the company while they're at it.
Then buy out the entire company once the oncolytic virus and oncarlytics show their safety after a Phase I.
Ann: Annual Report to shareholders, page-46
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
-0.002(2.82%) |
Mkt cap ! $505.0M | |||
| Open | High | Low | Value | Volume |
| 7.1¢ | 7.1¢ | 6.9¢ | $747.5K | 10.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1363554 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 1130620 | 10 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.002 ( 1.15 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.0¢ | 6.9¢ | 3175836 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| IMU (ASX) Chart |